Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock
09 Décembre 2019 - 10:18PM
Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a
clinical-stage biopharmaceutical company using its expertise in
epigenetics to discover and develop novel therapeutics, today
announced that it has commenced an underwritten public offering of
4.75 million shares of its common stock. All of the shares are
being offered by Constellation. In addition, Constellation expects
to grant the underwriters a 30-day option to purchase up to an
additional 15% of the shares of its common stock sold in the public
offering.
J.P. Morgan, Jefferies and Cowen are acting as joint
book-running managers for the offering. RBC Capital Markets is
acting as a bookrunner, and SunTrust Robinson Humphrey is acting as
lead manager for the offering. The offering is subject to market
and other conditions, and there can be no assurance as to whether
or when the offering may be completed, or as to the actual size or
terms of the offering.
The shares are being offered by Constellation pursuant to an
automatically effective shelf registration statement that was filed
with the Securities and Exchange Commission (“SEC”) on December 9,
2019.
This offering is being made only by means of a prospectus and
prospectus supplement that form a part of the registration
statement. A preliminary prospectus supplement relating to and
describing the terms of the offering is expected to be filed with
the SEC and, if and when filed, copies of the preliminary
prospectus supplement relating to the offering may be obtained for
free by visiting the SEC’s website at www.sec.gov. Copies of the
preliminary prospectus supplement and the accompanying prospectus
may also be obtained by contacting: J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, telephone: (866) 803-9204; Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, by telephone at 877-821-7388 or by email
at Prospectus_Department@Jefferies.com; or Cowen and Company, LLC,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, Attn: Prospectus Department, by email at
PostSaleManualRequests@broadridge.com or by telephone at (833)
297-2926. The final terms of the offering will be disclosed in a
final prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any sale of, these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals is a clinical-stage
biopharmaceutical company developing novel therapeutics that
selectively modulate gene expression to address serious unmet
medical needs in patients with cancer. The Company has a deep
understanding of how epigenetic and chromatin modifications in
cancer cells and in the tumor and immune microenvironment play a
fundamental role in driving disease progression and drug
resistance. Constellation is driving development of the BET
inhibitor CPI-0610 for the treatment of myelofibrosis as well as
the EZH2 inhibitors CPI-1205 and CPI-0209 for the treatment of
metastatic castration-resistant prostate cancer and other cancers.
The Company is also applying its broad research and development
capabilities to explore other novel targets that directly and
indirectly impact gene expression to fuel a sustainable pipeline of
innovative small-molecule product candidates.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995, such as those, among others, relating to the Company’s plans
to consummate its proposed public offering. The words “anticipate,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intend,”
“may,” “plan,” “potential,” “predict,” “project,” “should,”
“target,” “will,” “would” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Actual
results may differ materially from those projected or implied in
these forward-looking statements. Factors that may cause such a
difference include, without limitation, risks and uncertainties
related to whether or not the Company will be able to raise capital
through the sale of shares of common stock, the final terms of the
proposed offering, market and other conditions, the satisfaction of
customary closing conditions related to the proposed public
offering and the impact of general economic, industry or political
conditions in the United States or internationally. There can be no
assurance that the Company will be able to complete the proposed
public offering on the anticipated terms, or at all. You should not
place undue reliance on these forward-looking statements.
Additional risks and uncertainties relating to the proposed
offering, Constellation and its business can be found under the
caption “Risk Factors” included in the Company’s Quarterly Report
on Form 10-Q for the quarter ended September 30, 2019, the
Company’s preliminary prospectus supplement expected to be filed
with the SEC on December 9, 2019, and other filings that the
Company may make with the SEC in the future. In addition, the
forward-looking statements included in this press release represent
the Company’s views as of the date hereof and should not be relied
upon as representing the Company’s views as of any date subsequent
to the date hereof. The Company anticipates that subsequent events
and developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so.
Contacts
Ronald Aldridge Senior Director, Investor RelationsConstellation
Pharmaceuticals+1
617-714-0539ron.aldridge@constellationpharma.com
Lauren ArnoldMedia RelationsMacDougall Biomedical
Communications+1 781-235-3060larnold@macbiocom.com
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024